<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39412657</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1432-0614</ISSN><JournalIssue CitedMedium="Internet"><Volume>108</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>16</Day></PubDate></JournalIssue><Title>Applied microbiology and biotechnology</Title><ISOAbbreviation>Appl Microbiol Biotechnol</ISOAbbreviation></Journal><ArticleTitle>Design of the conserved epitope peptide of SARS-CoV-2 spike protein as the broad-spectrum COVID-19 vaccine.</ArticleTitle><Pagination><StartPage>486</StartPage><MedlinePgn>486</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">486</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00253-024-13331-y</ELocationID><Abstract><AbstractText>Our previous study has found that monoclonal antibodies targeting a conserved epitope peptide spanning from residues 1144 to 1156 of SARS-CoV-2 spike (S) protein, namely S(1144-1156), can broadly neutralize all of the prevalent SARS-CoV-2 strains, including the wild type, Alpha, Epsilon, Delta, and Gamma variants. In the study, S(1144-1156) was conjugated with bovine serum albumin (BSA) and formulated with Montanide ISA 51 adjuvant for inoculation in BALB/c mice to study its potential as a vaccine candidate. Results showed that the titers of S protein-specific IgGs and the neutralizing antibodies in mouse sera against various SARS-CoV-2 variants, including the Omicron sublineages, were largely induced along with three doses of immunization. The significant release of IFN-γ and IL-2 was also observed by ELISpot assays through stimulating vaccinated mouse splenocytes with the S(1144-1156) peptide. Furthermore, the vaccination of the S(1143-1157)- and S(1142-1158)-EGFP fusion proteins can elicit more SARS-CoV-2 neutralizing antibodies in mouse sera than the S(1144-1156)-EGFP fusion protein. Interestingly, the antisera collected from mice inoculated with the S(1144-1156) peptide vaccine exhibited better efficacy for neutralizing Omicron BA.2.86 and JN.1 subvariants than Omicron BA.1, BA.2, and XBB subvariants. Since the amino acid sequences of the S(1144-1156) are highly conserved among various SARS-CoV-2 variants, the immunogen containing the S(1144-1156) core epitope can be designed as a broadly effective COVID-19 vaccine. KEY POINTS: • Inoculation of mice with the S(1144-1156) peptide vaccine can induce bnAbs against various SARS-CoV-2 variants. • The S(1144-1156) peptide stimulated significant release of IFN-γ and IL-2 in vaccinated mouse splenocytes. • The S(1143-1157) and S(1142-1158) peptide vaccines can elicit more SARS-CoV-2 nAbs in mice.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Ting-Yu</ForeName><Initials>TY</Initials><AffiliationInfo><Affiliation>Department of Biochemical Science and Technology, College of Life Science, National Taiwan University, Taipei, 106, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Chia-Jung</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Biochemical Science and Technology, College of Life Science, National Taiwan University, Taipei, 106, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chao</LastName><ForeName>Tai-Ling</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, 100, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Sui-Yuan</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, 100, Taiwan. sychang@ntu.edu.tw.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine, College of Medicine, National Taiwan University Hospital, National Taiwan University, Taipei, 100, Taiwan. sychang@ntu.edu.tw.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Shih-Chung</ForeName><Initials>SC</Initials><Identifier Source="ORCID">0000-0002-5015-8178</Identifier><AffiliationInfo><Affiliation>Department of Biochemical Science and Technology, College of Life Science, National Taiwan University, Taipei, 106, Taiwan. shihchung@ntu.edu.tw.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Biotechnology, National Taiwan University, Taipei, 106, Taiwan. shihchung@ntu.edu.tw.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>111-2320-B-002-047</GrantID><Agency>National Science and Technology Council</Agency><Country /></Grant><Grant><GrantID>112-2740-B-002-004</GrantID><Agency>National Science and Technology Council</Agency><Country /></Grant><Grant><GrantID>112-2321-B-002-013</GrantID><Agency>National Science and Technology Council</Agency><Country /></Grant><Grant><GrantID>112L7255</GrantID><Agency>National Taiwan University</Agency><Country /></Grant><Grant><GrantID>113L7226</GrantID><Agency>National Taiwan University</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Appl Microbiol Biotechnol</MedlineTA><NlmUniqueID>8406612</NlmUniqueID><ISSNLinking>0175-7598</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="Y">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="Y">Epitopes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Broadly neutralizing antibody (bnAb)</Keyword><Keyword MajorTopicYN="N">Cellular immunity</Keyword><Keyword MajorTopicYN="N">Epitope peptide</Keyword><Keyword MajorTopicYN="N">Humoral immunity</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Spike protein</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>12</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>11</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39412657</ArticleId><ArticleId IdType="pmc">PMC11485143</ArticleId><ArticleId IdType="doi">10.1007/s00253-024-13331-y</ArticleId><ArticleId IdType="pii">10.1007/s00253-024-13331-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ai J, Zhang H, Zhang Y, Lin K, Zhang Y, Wu J, Wan Y, Huang Y, Song J, Fu Z, Wang H, Guo J, Jiang N, Fan M, Zhou Y, Zhao Y, Zhang Q, Liu Q, Lv J, Li P, Qiu C, Zhang W (2022) Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Emerg Microbes Infect 11(1):337–343</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8788341</ArticleId><ArticleId IdType="pubmed">34935594</ArticleId></ArticleIdList></Reference><Reference><Citation>Amanat F, Thapa M, Lei T, Ahmed SMS, Adelsberg DC, Carreno JM, Strohmeier S, Schmitz AJ, Zafar S, Zhou JQ, Rijnink W, Alshammary H, Borcherding N, Reiche AG, Srivastava K, Sordillo EM, van Bakel H, Personalized Virology I, Turner JS, Bajic G, Simon V, Ellebedy AH, Krammer F (2021) SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. Cell 184(15):3936–3948</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8185186</ArticleId><ArticleId IdType="pubmed">34192529</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbel R, Peretz A, Sergienko R, Friger M, Beckenstein T, Duskin-Bitan H, Yaron S, Hammerman A, Bilenko N, Netzer D (2023) Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study. Lancet Infect Dis 23(8):914–921</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10156150</ArticleId><ArticleId IdType="pubmed">37062302</ArticleId></ArticleIdList></Reference><Reference><Citation>Carreno JM, Alshammary H, Tcheou J, Singh G, Raskin AJ, Kawabata H, Sominsky LA, Clark JJ, Adelsberg DC, Bielak DA, Gonzalez-Reiche AS, Dambrauskas N, Vigdorovich V, Group P-PS, Srivastava K, Sather DN, Sordillo EM, Bajic G, van Bakel H, Simon V, Krammer F (2022) Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature 602(7898):682–688</Citation><ArticleIdList><ArticleId IdType="pubmed">35016197</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Guan F, Candotti F, Benlagha K, Camara NOS, Herrada AA, James LK, Lei J, Miller H, Kubo M, Ning Q, Liu C (2022) The role of B cells in COVID-19 infection and vaccination. Front Immunol 13:988536</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9468879</ArticleId><ArticleId IdType="pubmed">36110861</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi WY, Li YD, Huang HC, Chan TEH, Chow SY, Su JH, Ferrall L, Hung CF, Wu TC (2022) COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. J Biomed Sci 29(1):82</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9569411</ArticleId><ArticleId IdType="pubmed">36243868</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai L, Zheng T, Xu K, Han Y, Xu L, Huang E, An Y, Cheng Y, Li S, Liu M, Yang M, Li Y, Cheng H, Yuan Y, Zhang W, Ke C, Wong G, Qi J, Qin C, Yan J, Gao GF (2020) A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell 182(3):722–733</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7321023</ArticleId><ArticleId IdType="pubmed">32645327</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhawan M, Rabaan AA, Fawarah MMA, Almuthree SA, Alsubki RA, Alfaraj AH, Mashraqi MM, Alshamrani SA, Abduljabbar WA, Alwashmi ASS, Ibrahim FA, Alsaleh AA, Khamis F, Alsalman J, Sharma M, Emran TB (2023) Updated insights into the T cell-mediated immune response against SARS-CoV-2: a step towards efficient and reliable vaccines. Vaccines (Basel) 11(1):101</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9861463</ArticleId><ArticleId IdType="pubmed">36679947</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao F, Huang J, Li T, Hu C, Shen M, Mu S, Luo F, Song S, Hao Y, Wang W, Han X, Qian C, Wang Y, Wu R, Li L, Li S, Jin A (2021) A highly conserved peptide vaccine candidate activates both humoral and cellular immunity against SARS-CoV-2 variant strains. Front Immunol 12:789905</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8688401</ArticleId><ArticleId IdType="pubmed">34950151</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez CE, Perdiguero B, Esteban M (2021) Emerging SARS-CoV-2 variants and impact in global vaccination programs against SARS-CoV-2/COVID-19. Vaccines (Basel) 9(3):243</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7999234</ArticleId><ArticleId IdType="pubmed">33799505</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo K, Ni P, Chang S, Jin Y, Duan G, Zhang R (2023) Effectiveness of mRNA vaccine against Omicron-related infections in the real world: a systematic review and meta-analysis. Am J Infect Control 51(9):1049–1055</Citation><ArticleIdList><ArticleId IdType="pubmed">36801346</ArticleId></ArticleIdList></Reference><Reference><Citation>Hattab D, Amer MFA, Al-Alami ZM, Bakhtiar A (2024) SARS-CoV-2 journey: from alpha variant to omicron and its sub-variants. Infection 52(3):767–786</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11143066</ArticleId><ArticleId IdType="pubmed">38554253</ArticleId></ArticleIdList></Reference><Reference><Citation>He X, He C, Hong W, Yang J, Wei X (2023) Research progress in spike mutations of SARS-CoV-2 variants and vaccine development. Med Res Rev 43(4):932–971</Citation><ArticleIdList><ArticleId IdType="pubmed">36929527</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurlburt NK, Homad LJ, Sinha I, Jennewein MF, MacCamy AJ, Wan YH, Boonyaratanakornkit J, Sholukh AM, Jackson AM, Zhou P, Burton DR, Andrabi R, Ozorowski G, Ward AB, Stamatatos L, Pancera M, McGuire AT (2022) Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit. Commun Biol 5(1):342</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9001700</ArticleId><ArticleId IdType="pubmed">35411021</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain N, Shankar U, Majee P, Kumar A (2021) Scrutinizing the SARS-CoV-2 protein information for designing an effective vaccine encompassing both the T-cell and B-cell epitopes. Infect Genet Evol 87:104648</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7700730</ArticleId><ArticleId IdType="pubmed">33264668</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhlmann C, Mayer CK, Claassen M, Maponga T, Burgers WA, Keeton R, Riou C, Sutherland AD, Suliman T, Shaw ML, Preiser W (2022) Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. Lancet 399(10325):625–626</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8765759</ArticleId><ArticleId IdType="pubmed">35063123</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai GC, Chao TL, Lin SY, Kao HC, Tsai YM, Lu DC, Chiang YW, Chang SY, Chang SC (2022) Neutralization or enhancement of SARS-CoV-2 infection by a monoclonal antibody targeting a specific epitope in the spike receptor-binding domain. Antiviral Res 200:105290</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8918075</ArticleId><ArticleId IdType="pubmed">35296418</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L, Wang X (2020) Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581(7807):215–220</Citation><ArticleIdList><ArticleId IdType="pubmed">32225176</ArticleId></ArticleIdList></Reference><Reference><Citation>Li CJ, Chang SC (2023) SARS-CoV-2 spike S2-specific neutralizing antibodies. Emerg Microbes Infect 12(2):2220582</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10274517</ArticleId><ArticleId IdType="pubmed">37254830</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Kan Q, Ge J, Wan Z, Yuan M, Huang Y, Xie Q, Yang Y, Shao H, Li X, Ye L, Qin A, Bu Z, Liu P, Ye J (2021) A novel linear and broadly neutralizing peptide in the SARS-CoV-2 S2 protein for universal vaccine development. Cell Mol Immunol 18(11):2563–2565</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8513545</ArticleId><ArticleId IdType="pubmed">34645942</ArticleId></ArticleIdList></Reference><Reference><Citation>Li CJ, Chao TL, Chang TY, Hsiao CC, Lu DC, Chiang YW, Lai GC, Tsai YM, Fang JT, Ieong S, Wang JT, Chang SY, Chang SC (2022a) Neutralizing monoclonal antibodies inhibit SARS-CoV-2 infection through blocking membrane fusion. Microbiol Spectr 10(2):e0181421</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9045258</ArticleId><ArticleId IdType="pubmed">35293796</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Wei Y, Yang H, Yan J, Li X, Li Z, Zhao Y, Liang H, Wang H (2022b) Advances in next-generation coronavirus vaccines in response to future virus evolution. Vaccines (Basel) 10(12):2035</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9785936</ArticleId><ArticleId IdType="pubmed">36560445</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Y, Zhang J, Yuan RY, Wang MY, He P, Su JG, Han ZB, Jin YQ, Hou JW, Zhang H, Zhang XF, Shao S, Hou YN, Liu ZM, Du LF, Shen FJ, Zhou WM, Xu K, Gao RQ, Tang F, Lei ZH, Liu S, Zhen W, Wu JJ, Zheng X, Liu N, Chen S, Ma ZJ, Zheng F, Ren SY, Hu ZY, Huang WJ, Wu GZ, Ke CW, Li QM (2022) Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2. Cell Discov 8(1):17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8847466</ArticleId><ArticleId IdType="pubmed">35169113</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Rocklov J (2021) The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus. J Travel Med 28(7):taab124</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8436367</ArticleId><ArticleId IdType="pubmed">34369565</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Rocklov J (2022) The effective reproductive number of the Omicron variant of SARS-CoV-2 is several times relative to Delta. J Travel Med 29(3):taac037</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8992231</ArticleId><ArticleId IdType="pubmed">35262737</ArticleId></ArticleIdList></Reference><Reference><Citation>Manathunga SS, Abeyagunawardena IA, Dharmaratne SD (2023) A comparison of transmissibility of SARS-CoV-2 variants of concern. Virol J 20(1):59</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10067514</ArticleId><ArticleId IdType="pubmed">37009864</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss P (2022) The T cell immune response against SARS-CoV-2. Nat Immunol 23(2):186–193</Citation><ArticleIdList><ArticleId IdType="pubmed">35105982</ArticleId></ArticleIdList></Reference><Reference><Citation>Olukitibi TA, Ao Z, Warner B, Unat R, Kobasa D, Yao X (2023) Significance of conserved regions in coronavirus spike protein for developing a novel vaccine against SARS-CoV-2 infection. Vaccines (Basel) 11(3):545</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10056353</ArticleId><ArticleId IdType="pubmed">36992129</ArticleId></ArticleIdList></Reference><Reference><Citation>Pather S, Madhi SA, Cowling BJ, Moss P, Kamil JP, Ciesek S, Muik A, Tureci O (2023) SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines. Front Immunol 14:1130539</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10242031</ArticleId><ArticleId IdType="pubmed">37287979</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettini E, Medaglini D, Ciabattini A (2022) Profiling the B cell immune response elicited by vaccination against the respiratory virus SARS-CoV-2. Front Immunol 13:1058748</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9729280</ArticleId><ArticleId IdType="pubmed">36505416</ArticleId></ArticleIdList></Reference><Reference><Citation>Piepenbrink MS, Park JG, Deshpande A, Loos A, Ye C, Basu M, Sarkar S, Khalil AM, Chauvin D, Woo J, Lovalenti P, Erdmann NB, Goepfert PA, Truong VL, Bowen RA, Walter MR, Martinez-Sobrido L, Kobie JJ (2022) Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody. PLoS Pathog 18(7):e1010691</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9302814</ArticleId><ArticleId IdType="pubmed">35862475</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto D, Sauer MM, Czudnochowski N, Low JS, Tortorici MA, Housley MP, Noack J, Walls AC, Bowen JE, Guarino B, Rosen LE, di Iulio J, Jerak J, Kaiser H, Islam S, Jaconi S, Sprugasci N, Culap K, Abdelnabi R, Foo C, Coelmont L, Bartha I, Bianchi S, Silacci-Fregni C, Bassi J, Marzi R, Vetti E, Cassotta A, Ceschi A, Ferrari P, Cippa PE, Giannini O, Ceruti S, Garzoni C, Riva A, Benigni F, Cameroni E, Piccoli L, Pizzuto MS, Smithey M, Hong D, Telenti A, Lempp FA, Neyts J, Havenar-Daughton C, Lanzavecchia A, Sallusto F, Snell G, Virgin HW, Beltramello M, Corti D, Veesler D (2021) Broad betacoronavirus neutralization by a stem helix-specific human antibody. Science 373(6559):1109–1116</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9268357</ArticleId><ArticleId IdType="pubmed">34344823</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, Bolland WH, Porrot F, Staropoli I, Lemoine F, Pere H, Veyer D, Puech J, Rodary J, Baele G, Dellicour S, Raymenants J, Gorissen S, Geenen C, Vanmechelen B, Wawina-Bokalanga T, Marti-Carreras J, Cuypers L, Seve A, Hocqueloux L, Prazuck T, Rey FA, Simon-Loriere E, Bruel T, Mouquet H, Andre E, Schwartz O (2022) Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 602(7898):671–675</Citation><ArticleIdList><ArticleId IdType="pubmed">35016199</ArticleId></ArticleIdList></Reference><Reference><Citation>Plumb ID, Briggs Hagen M, Wiegand R, Dumyati G, Myers C, Harland KK, Krishnadasan A, James Gist J, Abedi G, Fleming-Dutra KE, Chea N, Lee JE, Kellogg M, Edmundson A, Britton A, Wilson LE, Lovett SA, Ocampo V, Markus TM, Smithline HA, Hou PC, Lee LC, Mower W, Rwamwejo F, Steele MT, Lim SC, Schrading WA, Chinnock B, Beiser DG, Faine B, Haran JP, Nandi U, Chipman AK, LoVecchio F, Eucker S, Femling J, Fuller M, Rothman RE, Curlin ME, Talan DA, Mohr NM, Vaccine Effectiveness among Healthcare Personnel Study T (2024) Effectiveness of a bivalent mRNA vaccine dose against symptomatic SARS-CoV-2 infection among U.S. Healthcare personnel, September 2022-May 2023. Vaccine 42(10):2543–2552</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10994739</ArticleId><ArticleId IdType="pubmed">37973512</ArticleId></ArticleIdList></Reference><Reference><Citation>Sah R, Rais MA, Mohanty A, Chopra H, Chandran D, Bin Emran T, Dhama K (2023) Omicron (B.1.1.529) variant and its subvariants and lineages may lead to another COVID-19 wave in the world? -An overview of current evidence and counteracting strategies. Int J Surg Open 55:100625</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10192062</ArticleId><ArticleId IdType="pubmed">37255735</ArticleId></ArticleIdList></Reference><Reference><Citation>Senevirathne TH, Wekking D, Swain JWR, Solinas C, De Silva P (2024) COVID-19: from emerging variants to vaccination. Cytokine Growth Factor Rev 76:127–141</Citation><ArticleIdList><ArticleId IdType="pubmed">38135574</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah P, Canziani GA, Carter EP, Chaiken I (2021) The case for S2: the potential benefits of the S2 subunit of the SARS-CoV-2 spike protein as an immunogen in fighting the COVID-19 pandemic. Front Immunol 12:637651</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7985173</ArticleId><ArticleId IdType="pubmed">33767706</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CW, Valkenburg SA, Poon LLM, Wang LF (2023) Broad-spectrum pan-genus and pan-family virus vaccines. Cell Host Microbe 31(6):902–916</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10265776</ArticleId><ArticleId IdType="pubmed">37321173</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, Zhou D, Ginn HM, Selvaraj M, Liu C, Mentzer AJ, Supasa P, Duyvesteyn HME, Das R, Skelly D, Ritter TG, Amini A, Bibi S, Adele S, Johnson SA, Constantinides B, Webster H, Temperton N, Klenerman P, Barnes E, Dunachie SJ, Crook D, Pollard AJ, Lambe T, Goulder P, Paterson NG, Williams MA, Hall DR, Consortium O, Consortium IC, Fry EE, Huo J, Mongkolsapaya J, Ren J, Stuart DI, Screaton GR (2022) Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell 185(14):2422–2433</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9181312</ArticleId><ArticleId IdType="pubmed">35772405</ArticleId></ArticleIdList></Reference><Reference><Citation>Urschel R, Bronder S, Klemis V, Marx S, Hielscher F, Abu-Omar A, Guckelmus C, Schneitler S, Baum C, Becker SL, Gartner BC, Sester U, Martinez L, Widera M, Schmidt T, Sester M (2024) SARS-CoV-2-specific cellular and humoral immunity after bivalent BA.4/5 COVID-19-vaccination in previously infected and non-infected individuals. Nat Commun 15(1):3077</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11004149</ArticleId><ArticleId IdType="pubmed">38594497</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D (2020) Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181(2):281–292</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102599</ArticleId><ArticleId IdType="pubmed">32155444</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang MY, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM (2020) SARS-CoV-2: structure, biology, and structure-based therapeutics development. Front Cell Infect Microbiol 10:587269</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7723891</ArticleId><ArticleId IdType="pubmed">33324574</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Wang S, Zhang Y, Yuan L, Zheng Q, Wei M, Shi Y, Wang Z, Ma J, Wang K, Nie M, Xiao J, Huang Z, Chen P, Guo H, Lan M, Xu J, Hou W, Hong Y, Chen D, Sun H, Xiong H, Zhou M, Liu C, Guo W, Guo H, Gao J, Gan C, Li Z, Zhang H, Wang X, Li S, Cheng T, Zhao Q, Chen Y, Wu T, Zhang T, Zhang J, Cao H, Zhu H, Yuan Q, Guan Y, Xia N (2022) Lineage-mosaic and mutation-patched spike proteins for broad-spectrum COVID-19 vaccine. Cell Host Microbe 30(12):1732–1744</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9576691</ArticleId><ArticleId IdType="pubmed">36323313</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu K, Gao P, Liu S, Lu S, Lei W, Zheng T, Liu X, Xie Y, Zhao Z, Guo S, Tang C, Yang Y, Yu W, Wang J, Zhou Y, Huang Q, Liu C, An Y, Zhang R, Han Y, Duan M, Wang S, Yang C, Wu C, Liu X, She G, Liu Y, Zhao X, Xu K, Qi J, Wu G, Peng X, Dai L, Wang P, Gao GF (2022) Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. Cell 185(13):2265–2278</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9042943</ArticleId><ArticleId IdType="pubmed">35568034</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Wang W, Chen Z, Lu S, Yang F, Bi Z, Bao L, Mo F, Li X, Huang Y, Hong W, Yang Y, Zhao Y, Ye F, Lin S, Deng W, Chen H, Lei H, Zhang Z, Luo M, Gao H, Zheng Y, Gong Y, Jiang X, Xu Y, Lv Q, Li D, Wang M, Li F, Wang S, Wang G, Yu P, Qu Y, Yang L, Deng H, Tong A, Li J, Wang Z, Yang J, Shen G, Zhao Z, Li Y, Luo J, Liu H, Yu W, Yang M, Xu J, Wang J, Li H, Wang H, Kuang D, Lin P, Hu Z, Guo W, Cheng W, He Y, Song X, Chen C, Xue Z, Yao S, Chen L, Ma X, Chen S, Gou M, Huang W, Wang Y, Fan C, Tian Z, Shi M, Wang F-S, Dai L, Wu M, Li G, Wang G, Peng Y, Qian Z, Huang C, Lau JY-N, Yang Z, Wei Y, Cen X, Peng X, Qin C, Zhang K, Lu G, Wei X (2020) A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature 586(7830):572–577</Citation><ArticleIdList><ArticleId IdType="pubmed">32726802</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan M, Liu H, Wu NC, Lee C-CD, Zhu X, Zhao F, Huang D, Yu W, Hua Y, Tien H, Rogers TF, Landais E, Sok D, Jardine JG, Burton DR, Wilson IA (2020) Structural basis of a shared antibody response to SARS-CoV-2. Science 369(6507):1119–1123</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402627</ArticleId><ArticleId IdType="pubmed">32661058</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao F, Zai X, Zhang Z, Xu J, Chen W (2022) Challenges and developments in universal vaccine design against SARS-CoV-2 variants. NPJ Vaccines 7(1):167</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9761649</ArticleId><ArticleId IdType="pubmed">36535982</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P, Yuan M, Song G, Beutler N, Shaabani N, Huang D, He WT, Zhu X, Callaghan S, Yong P, Anzanello F, Peng L, Ricketts J, Parren M, Garcia E, Rawlings SA, Smith DM, Nemazee D, Teijaro JR, Rogers TF, Wilson IA, Burton DR, Andrabi R (2022) A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection. Sci Transl Med 14(637):eabi9215</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8939767</ArticleId><ArticleId IdType="pubmed">35133175</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu C, Pang S, Liu J, Duan Q (2024) Current progress, challenges and prospects in the development of COVID-19 vaccines. Drugs 84(4):403–423</Citation><ArticleIdList><ArticleId IdType="pubmed">38652356</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>